# Diodes Inc: financial statements, quarterly

DIOD · Nasdaq · CIK 29002 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/diod.md) · [Financials](/companies/diod/financials.md) · [Filings](/companies/diod/filings.md) · [Insiders](/companies/diod/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/diod/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [405](/filings/0000950170-24-123507.md) | [323 d](/filings/0001193125-26-044918.md) | [302](/filings/0000950170-25-067170.md) | [320](/filings/0000950170-25-105233.md) | [350](/filings/0001193125-25-270081.md) | [339 d](/filings/0001193125-26-044918.md) | [332](/filings/0001193125-26-212380.md) | [366](/filings/0001193125-26-335450.md) | [392](/filings/0001193125-25-270081.md) | [392 d](/filings/0001193125-26-044918.md) | [405](/filings/0001193125-26-212380.md) | [446](/filings/0001193125-26-335450.md) |
| Cost of revenue | $m | [249](/filings/0000950170-24-123507.md) | [210 d](/filings/0001193125-26-044918.md) | [202](/filings/0000950170-25-067170.md) | [212](/filings/0000950170-25-105233.md) | [232](/filings/0001193125-25-270081.md) | [228 d](/filings/0001193125-26-044918.md) | [227](/filings/0001193125-26-212380.md) | [251](/filings/0001193125-26-335450.md) | [272](/filings/0001193125-25-270081.md) | [270 d](/filings/0001193125-26-044918.md) | [277](/filings/0001193125-26-212380.md) | [298](/filings/0001193125-26-335450.md) |
| Gross profit | $m | [156](/filings/0000950170-24-123507.md) | [112 d](/filings/0001193125-26-044918.md) | [99.6](/filings/0000950170-25-067170.md) | [107](/filings/0000950170-25-105233.md) | [118](/filings/0001193125-25-270081.md) | [111 d](/filings/0001193125-26-044918.md) | [105](/filings/0001193125-26-212380.md) | [115](/filings/0001193125-26-335450.md) | [120](/filings/0001193125-25-270081.md) | [122 d](/filings/0001193125-26-044918.md) | [129](/filings/0001193125-26-212380.md) | [148](/filings/0001193125-26-335450.md) |
| Research and development | $m | [34.1](/filings/0000950170-24-123507.md) | [33.0 d](/filings/0001193125-26-044918.md) | [34.0](/filings/0000950170-25-067170.md) | [33.2](/filings/0000950170-25-105233.md) | [33.7](/filings/0001193125-25-270081.md) | [33.2 d](/filings/0001193125-26-044918.md) | [38.6](/filings/0001193125-26-212380.md) | [40.5](/filings/0001193125-26-335450.md) | [41.9](/filings/0001193125-25-270081.md) | [41.2 d](/filings/0001193125-26-044918.md) | [40.6](/filings/0001193125-26-212380.md) | [40.7](/filings/0001193125-26-335450.md) |
| Selling, general and administrative | $m | [63.0](/filings/0000950170-24-123507.md) | [56.5 d](/filings/0001193125-26-044918.md) | [53.7](/filings/0000950170-25-067170.md) | [58.5](/filings/0000950170-25-105233.md) | [59.4](/filings/0001193125-25-270081.md) | [62.3 d](/filings/0001193125-26-044918.md) | [58.7](/filings/0001193125-26-212380.md) | [59.5](/filings/0001193125-26-335450.md) | [60.5](/filings/0001193125-25-270081.md) | [62.9 d](/filings/0001193125-26-044918.md) | [64.3](/filings/0001193125-26-212380.md) | [69.8](/filings/0001193125-26-335450.md) |
| Operating income | $m | [53.9](/filings/0000950170-24-123507.md) | [20.7 d](/filings/0001193125-26-044918.md) | [12.9](/filings/0000950170-25-067170.md) | [3.7](/filings/0000950170-25-105233.md) | [21.9](/filings/0001193125-25-270081.md) | [11.9 d](/filings/0001193125-26-044918.md) | [1.3](/filings/0001193125-26-212380.md) | [9.4](/filings/0001193125-26-335450.md) | [11.6](/filings/0001193125-25-270081.md) | [13.2 d](/filings/0001193125-26-044918.md) | [19.8](/filings/0001193125-26-212380.md) | [33.3](/filings/0001193125-26-335450.md) |
| Interest expense | $m | [0.9](/filings/0000950170-24-123507.md) | [0.5 d](/filings/0000950170-25-021400.md) | [0.5](/filings/0000950170-24-057252.md) | [0.9](/filings/0000950170-24-094180.md) | [0.5](/filings/0000950170-24-123507.md) | [0.5 d](/filings/0000950170-25-021400.md) | [0.5](/filings/0001193125-26-212380.md) | [0.5](/filings/0001193125-26-335450.md) | [0.5](/filings/0001193125-25-270081.md) | [1.3 d](/filings/0001193125-26-044918.md) | [0.7](/filings/0001193125-26-212380.md) | [0.3](/filings/0001193125-26-335450.md) |
| Income tax | $m | [10.7](/filings/0000950170-24-123507.md) | [2.8 d](/filings/0001193125-26-044918.md) | [3.5](/filings/0000950170-25-067170.md) | [2.6](/filings/0000950170-25-105233.md) | [3.6](/filings/0001193125-25-270081.md) | [2.0 d](/filings/0001193125-26-044918.md) | [0.0](/filings/0001193125-26-212380.md) | [9.1](/filings/0001193125-26-335450.md) | [3.6](/filings/0001193125-25-270081.md) | [2.2 d](/filings/0001193125-26-044918.md) | [4.0](/filings/0001193125-26-212380.md) | [6.8](/filings/0001193125-26-335450.md) |
| Net income | $m | [48.7](/filings/0000950170-24-123507.md) | [25.3 d](/filings/0001193125-26-044918.md) | [14.0](/filings/0000950170-25-067170.md) | [8.0](/filings/0000950170-25-105233.md) | [13.7](/filings/0001193125-25-270081.md) | [8.2 d](/filings/0001193125-26-044918.md) | [(4.4)](/filings/0001193125-26-212380.md) | [46.1](/filings/0001193125-26-335450.md) | [14.3](/filings/0001193125-25-270081.md) | [10.2 d](/filings/0001193125-26-044918.md) | [15.0](/filings/0001193125-26-212380.md) | [46.6](/filings/0001193125-26-335450.md) |
| Diluted EPS | $ per share | [1.05](/filings/0000950170-24-123507.md) | not reported | [0.30](/filings/0000950170-25-067170.md) | [0.17](/filings/0000950170-25-105233.md) | [0.30](/filings/0001193125-25-270081.md) | not reported | [(0.10)](/filings/0001193125-26-212380.md) | [0.99](/filings/0001193125-26-335450.md) | [0.31](/filings/0001193125-25-270081.md) | not reported | [0.32](/filings/0001193125-26-212380.md) | [1.00](/filings/0001193125-26-335450.md) |
| Basic EPS | $ per share | [1.06](/filings/0000950170-24-123507.md) | not reported | [0.30](/filings/0000950170-25-067170.md) | [0.17](/filings/0000950170-25-105233.md) | [0.30](/filings/0001193125-25-270081.md) | not reported | [(0.10)](/filings/0001193125-26-212380.md) | [0.99](/filings/0001193125-26-335450.md) | [0.31](/filings/0001193125-25-270081.md) | not reported | [0.33](/filings/0001193125-26-212380.md) | [1.02](/filings/0001193125-26-335450.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [295](/filings/0000950170-23-061252.md) | [315](/filings/0000950170-25-021400.md) | [266](/filings/0000950170-24-057252.md) | [265](/filings/0000950170-24-094180.md) | [312](/filings/0000950170-24-123507.md) | [309](/filings/0001193125-26-044918.md) | [336](/filings/0000950170-25-067170.md) | [317](/filings/0000950170-25-105233.md) | [377](/filings/0001193125-25-270081.md) | [367](/filings/0001193125-26-335450.md) | [394](/filings/0001193125-26-212380.md) | [430](/filings/0001193125-26-335450.md) |
| Current assets | $m | [1,183](/filings/0000950170-23-061252.md) | [1,187](/filings/0000950170-25-021400.md) | [1,201](/filings/0000950170-24-057252.md) | [1,220](/filings/0000950170-24-094180.md) | [1,262](/filings/0000950170-24-123507.md) | [1,224](/filings/0001193125-26-044918.md) | [1,225](/filings/0000950170-25-067170.md) | [1,245](/filings/0000950170-25-105233.md) | [1,274](/filings/0001193125-25-270081.md) | [1,257](/filings/0001193125-26-335450.md) | [1,303](/filings/0001193125-26-212380.md) | [1,360](/filings/0001193125-26-335450.md) |
| Total assets | $m | [2,340](/filings/0000950170-24-123507.md) | [2,368](/filings/0001193125-26-044918.md) | [2,356](/filings/0000950170-25-067170.md) | [2,361](/filings/0000950170-25-105233.md) | [2,389](/filings/0001193125-25-270081.md) | [2,386](/filings/0001193125-26-044918.md) | [2,356](/filings/0001193125-26-212380.md) | [2,472](/filings/0001193125-26-335450.md) | [2,470](/filings/0001193125-25-270081.md) | [2,448](/filings/0001193125-26-335450.md) | [2,498](/filings/0001193125-26-212380.md) | [2,583](/filings/0001193125-26-335450.md) |
| Current liabilities | $m | [415](/filings/0000950170-23-061252.md) | [393](/filings/0000950170-25-021400.md) | [377](/filings/0000950170-24-057252.md) | [361](/filings/0000950170-24-094180.md) | [353](/filings/0000950170-24-123507.md) | [376](/filings/0001193125-26-044918.md) | [357](/filings/0000950170-25-067170.md) | [374](/filings/0000950170-25-105233.md) | [384](/filings/0001193125-25-270081.md) | [378](/filings/0001193125-26-335450.md) | [411](/filings/0001193125-26-212380.md) | [429](/filings/0001193125-26-335450.md) |
| Total liabilities | $m | [581](/filings/0000950170-23-061252.md) | [558](/filings/0000950170-25-021400.md) | [531](/filings/0000950170-24-057252.md) | [509](/filings/0000950170-24-094180.md) | [506](/filings/0000950170-24-123507.md) | [517](/filings/0001193125-26-044918.md) | [485](/filings/0000950170-25-067170.md) | [537](/filings/0000950170-25-105233.md) | [522](/filings/0001193125-25-270081.md) | [510](/filings/0001193125-26-335450.md) | [547](/filings/0001193125-26-212380.md) | [561](/filings/0001193125-26-335450.md) |
| Long-term debt | $m | [23.8](/filings/0000950170-23-061252.md) | [21.4](/filings/0000950170-25-021400.md) | [20.9](/filings/0000950170-24-057252.md) | [20.3](/filings/0000950170-24-094180.md) | [22.2](/filings/0000950170-24-123507.md) | [20.7](/filings/0001193125-26-044918.md) | [20.5](/filings/0000950170-25-067170.md) | [26.4](/filings/0000950170-25-105233.md) | [24.9](/filings/0001193125-25-270081.md) | [25.7](/filings/0001193125-26-335450.md) | [25.3](/filings/0001193125-26-212380.md) | [21.9](/filings/0001193125-26-335450.md) |
| Current portion of debt | $m | [1.1](/filings/0000950170-23-061252.md) | [4.4](/filings/0000950170-25-021400.md) | [1.3](/filings/0000950170-24-057252.md) | [1.3](/filings/0000950170-24-094180.md) | [1.4](/filings/0000950170-24-123507.md) | [1.1](/filings/0001193125-26-044918.md) | [1.4](/filings/0000950170-25-067170.md) | [1.6](/filings/0000950170-25-105233.md) | [4.8](/filings/0001193125-25-270081.md) | [1.4](/filings/0001193125-26-335450.md) | [1.6](/filings/0001193125-26-212380.md) | [1.6](/filings/0001193125-26-335450.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,690](/filings/0000950170-23-061252.md) | [1,741](/filings/0000950170-25-021400.md) | [1,749](/filings/0000950170-24-057252.md) | [1,774](/filings/0000950170-24-094180.md) | [1,812](/filings/0000950170-24-123507.md) | [1,795](/filings/0001193125-26-044918.md) | [1,801](/filings/0000950170-25-067170.md) | [1,877](/filings/0000950170-25-105233.md) | [1,889](/filings/0001193125-25-270081.md) | [1,878](/filings/0001193125-26-335450.md) | [1,889](/filings/0001193125-26-212380.md) | [1,952](/filings/0001193125-26-335450.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [50.1 d](/filings/0000950170-24-123507.md) | [38.4 d](/filings/0001193125-26-044918.md) | [(31.1)](/filings/0000950170-25-067170.md) | [14.4 d](/filings/0000950170-25-105233.md) | [54.4 d](/filings/0001193125-25-270081.md) | [81.8 d](/filings/0001193125-26-044918.md) | [56.7](/filings/0001193125-26-212380.md) | [41.5 d](/filings/0001193125-26-335450.md) | [79.1 d](/filings/0001193125-25-270081.md) | [38.1 d](/filings/0001193125-26-044918.md) | [64.3](/filings/0001193125-26-212380.md) | [68.5 d](/filings/0001193125-26-335450.md) |
| Capital expenditure | $m | [38.5 d](/filings/0000950170-24-123507.md) | [27.3 d](/filings/0001193125-26-044918.md) | [20.4](/filings/0000950170-25-067170.md) | [17.9 d](/filings/0000950170-25-105233.md) | [15.0 d](/filings/0001193125-25-270081.md) | [19.7 d](/filings/0001193125-26-044918.md) | [15.9](/filings/0001193125-26-212380.md) | [20.4 d](/filings/0001193125-26-335450.md) | [16.3 d](/filings/0001193125-25-270081.md) | [25.7 d](/filings/0001193125-26-044918.md) | [31.9](/filings/0001193125-26-212380.md) | [33.6 d](/filings/0001193125-26-335450.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-270081.md) | [0.0 d](/filings/0001193125-26-044918.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-270081.md) | [23.8 d](/filings/0001193125-26-044918.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.0](/filings/0000950170-23-061252.md) | [46.2](/filings/0000950170-24-057252.md) | [46.2](/filings/0000950170-24-094180.md) | [46.3](/filings/0000950170-24-123507.md) | [46.3](/filings/0000950170-25-067170.md) | [46.3](/filings/0000950170-25-105233.md) | [46.4](/filings/0001193125-25-270081.md) | [46.4](/filings/0001193125-26-212380.md) | [46.5](/filings/0001193125-26-335450.md) | [46.4](/filings/0001193125-25-270081.md) | [46.1](/filings/0001193125-26-212380.md) | [46.4](/filings/0001193125-26-335450.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,051,705 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335450.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.